Enzalutamide + NSAA + LHRHA or Surgical Castration
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Prostatic Neoplasms
Conditions
Prostatic Neoplasms
Trial Timeline
Mar 1, 2014 → Jun 30, 2027
NCT ID
NCT02446405About Enzalutamide + NSAA + LHRHA or Surgical Castration
Enzalutamide + NSAA + LHRHA or Surgical Castration is a phase 3 stage product being developed by Astellas Pharma for Prostatic Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT02446405. Target conditions include Prostatic Neoplasms.
What happened to similar drugs?
15 of 20 similar drugs in Prostatic Neoplasms were approved
Approved (15) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02446405 | Phase 3 | Active |
Competing Products
20 competing products in Prostatic Neoplasms